<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890770</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-061</org_study_id>
    <secondary_id>2018-002533-38</secondary_id>
    <nct_id>NCT03890770</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS-986165 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Renal Impairment and in Participants With End-Stage Renal Disease (ESRD) on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate BMS-986165 in participants with different levels
      of kidney function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Actual">February 13, 2020</completion_date>
  <primary_completion_date type="Actual">February 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Approximately 9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Approximately 9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Approximately 9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation</measure>
    <time_frame>Approximately 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations</measure>
    <time_frame>Approximately 45 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End-stage renal disease requiring dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two single doses administered with washout</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>End-stage renal disease requiring dialysis</arm_group_label>
    <arm_group_label>Mild renal disease</arm_group_label>
    <arm_group_label>Moderate renal failure</arm_group_label>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_label>Severe renal failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Participants must be judged to be in good health in the opinion of the investigator OR
             participant has a stable disease (eg, hypertension, hyperlipidemia, diabetes mellitus,
             hyperthyreosis) under medical control (ie, no changes in medication within 30 days
             prior to study drug administration)

          -  Stable renal impairment, defined as no clinically significant change in disease
             status, as documented by the participant's most recent eGFR assessment; eGFR must not
             vary more than 30% from screening to Day -1 to confirm stable renal function, and the
             renal impairment must be expected by the investigator not to change significantly
             during the next 3 months

          -  Body mass index of 18.0 to 38.0 kg/m2, inclusive, and weight ≥50 kg, at screening

        Exclusion Criteria:

          -  Clinically relevant abnormal medical history, abnormal findings on physical
             examination, vital signs, ECG, or laboratory tests at screening that the investigator
             judges as likely to interfere with the objectives of the trial or the safety of the
             participant

          -  Have a history of cancer (malignancy) with the following exceptions: (1) subjects with
             adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix
             may participate in the trial; (2) subjects with other malignancies that have been
             successfully treated ≥10 years prior to the screening visit where, in the judgment of
             both the investigator and treating physician, appropriate follow-up has revealed no
             evidence of recurrence from the time of treatment through the time of the screening
             visit

          -  History or clinical evidence of acute or chronic bacterial infection (eg, pneumonia,
             septicemia) within 3 months prior to screening

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates CZ, s.r.o</name>
      <address>
        <city>Praha 7</city>
        <zip>170 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Imre Egyetemi Oktatokorhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Korhaz es Rendelointezet</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Secjalistyczny Szpital Zachodni im. sw. Jana Pawla II</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Centrum Medyczne Chirurgii Maloinwazyjnej SCM</name>
      <address>
        <city>Krakow</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

